Glenmark Pharmaceuticals has introduced a new generic therapy for anemia in the United States, strengthening its footprint in one of the world’s most competitive pharmaceutical markets. The launch underscores the company’s ongoing efforts to expand its presence in specialty and chronic-care segments through high-quality, cost-effective alternatives. With demand for affordable anemia treatments rising across the U.S. healthcare system, Glenmark’s latest offering is positioned to support both patient access and market competitiveness.